Clinical Trials Directory

Trials / Completed

CompletedNCT00201916

Shorter Radiation Schedule for the Treatment of Prostate Cancer

A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
936 (actual)
Sponsor
Ontario Clinical Oncology Group (OCOG) · Academic / Other
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

To improve the management of patients with early stage prostate cancer.

Detailed description

To compare the efficacy of a shorter radiation fractionation schedule to the prostate (5250 cGy/20 fractions over 28 days) with a conventional schedule (6600 cGy/33 fractions over 45 days) in men receiving radiotherapy for Stage T1a moderately or poorly differentiated, or T1b, T1c, or T2 prostate cancer. The primary outcome is local control in the prostate and secondary outcomes include toxicity, disease free survival, survival, quality of life and economics.

Conditions

Interventions

TypeNameDescription
PROCEDURE5250 cGy/20 fractions over 28 dayssee above
PROCEDURE6600 cGy/33 fractions over 45 dayssee above

Timeline

Start date
1995-03-01
Primary completion
2008-12-01
Completion
2009-12-01
First posted
2005-09-20
Last updated
2010-08-17

Locations

16 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT00201916. Inclusion in this directory is not an endorsement.

Shorter Radiation Schedule for the Treatment of Prostate Cancer (NCT00201916) · Clinical Trials Directory